Rocket One Inc. RKTO
Rocket One Inc. (Nasdaq: RKTO) is a dermatology life-science company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| HT-001 | EGFR-inhibitor-associated skin rash (topical; Phase 2a open-label and double-blind randomized cohorts enrolling, US and EU) | small molecule | Phase 2 |
| BioLexa | Atopic dermatitis (Phase 1b completed 2022; no further Australian trials planned) | small molecule | Phase 1 |
| HT-KIT | Mast cell neoplasms and anaphylaxis (IND-enabling studies) | small molecule | Pre-clinical |
| HT-ALZ | Alzheimer's disease / neuroinflammation (formulation and animal work) | small molecule | Pre-clinical |
| HT-VA | Obesity and related conditions (GDNF) | protein/peptide | Pre-clinical |
| HT-004 | Asthma and allergies (inhaled exon-skipping oligonucleotide) | oligonucleotide-other | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.